Edwards Lifesciences Corp (NYSE:EW) CEO Sells $4,321,849.00 in Stock

Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 22,850 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $189.14, for a total transaction of $4,321,849.00. Following the transaction, the chief executive officer now owns 105,770 shares in the company, valued at approximately $20,005,337.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NYSE EW opened at $191.45 on Friday. The business has a 50-day moving average of $182.93. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $39.98 billion, a PE ratio of 40.73, a PEG ratio of 2.44 and a beta of 0.85. Edwards Lifesciences Corp has a 12 month low of $134.53 and a 12 month high of $197.86.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The company had revenue of $993.00 million during the quarter, compared to analyst estimates of $989.87 million. During the same period in the prior year, the firm earned $1.22 earnings per share. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. Research analysts forecast that Edwards Lifesciences Corp will post 5.29 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in EW. Norges Bank purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $559,646,000. FMR LLC lifted its stake in Edwards Lifesciences by 28.9% in the fourth quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock worth $1,160,540,000 after acquiring an additional 1,700,199 shares during the period. Jennison Associates LLC lifted its stake in Edwards Lifesciences by 40.2% in the first quarter. Jennison Associates LLC now owns 5,763,824 shares of the medical research company’s stock worth $1,102,792,000 after acquiring an additional 1,651,691 shares during the period. Legal & General Group Plc purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $168,766,000. Finally, BlackRock Inc. lifted its stake in Edwards Lifesciences by 4.7% in the first quarter. BlackRock Inc. now owns 17,211,498 shares of the medical research company’s stock worth $3,293,075,000 after acquiring an additional 780,079 shares during the period. 82.00% of the stock is owned by institutional investors.

A number of research analysts have weighed in on the stock. Stifel Nicolaus cut shares of Owens Corning from a “buy” rating to a “hold” rating and set a $52.45 price objective on the stock. in a research report on Wednesday, April 24th. Raymond James reiterated an “outperform” rating and set a C$44.00 price objective on shares of Teck Resources in a research report on Wednesday, April 24th. Zacks Investment Research cut shares of CGI from a “buy” rating to a “hold” rating in a report on Wednesday, June 19th. Deutsche Bank upped their price target on shares of Texas Instruments from $100.00 to $110.00 and gave the stock a “hold” rating in a report on Wednesday, April 24th. Finally, Canaccord Genuity set a $40.00 price target on shares of Mallinckrodt and gave the stock a “buy” rating in a report on Monday, March 18th. Two analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company. Edwards Lifesciences has a consensus rating of “Buy” and a consensus price target of $188.10.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: What is a Stop Order?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.